Leg Ulcers and Hydroxyurea | Zendy

Marie-Emmanuelle Sirieix | Zendy; C. Debure | Zendy; N. Baudot | Zendy; Louis Dubertret | Zendy; M Roux | Zendy; P Morel | Zendy; C. Françès | Zendy; S. Loubeyres | Zendy; C Beylot | Zendy; Donald H. Lambert | Zendy; P. Humbert | Zendy; O Gauthier | Zendy; M. Dandurand | Zendy; B. Guillot | Zendy; L. Vaillant | Zendy; G Lorette | Zendy; J.-M. Bonnetblanc | Zendy; C. Lok | Zendy; J P Denoeux | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Leg Ulcers and Hydroxyurea

Author(s) -

Marie-Emmanuelle Sirieix,

C. Debure,

N. Baudot,

Louis Dubertret,

M Roux,

P Morel,

C. Françès,

S. Loubeyres,

C Beylot,

Donald H. Lambert,

P. Humbert,

O Gauthier,

M. Dandurand,

B. Guillot,

L. Vaillant,

G Lorette,

J.-M. Bonnetblanc,

C. Lok,

J P Denoeux

Publication year - 1999

Publication title -

archives of dermatology

Language(s) - English

Resource type - Journals

eISSN - 1538-3652

pISSN - 0003-987X

DOI - 10.1001/archderm.135.7.818

Subject(s) - medicine , hydroxycarbamide , adverse effect , disease , atrophy , surgery , vascular disease , prospective cohort study

Hydroxyurea is an antitumor agent used to treat chronic myeloproliferative disorders. Leg ulcerations have been reported in patients undergoing long-term hydroxyurea therapy for myeloproliferative diseases. To better define this dermatological adverse effect of hydroxyurea therapy and to try to understand the pathophysiological process of this disease, we collected medical information for such patients in a multicenter retrospective study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research